Payment overview · 2025
General Payments
$2,472.93
169 reported records · 23 companies
Healthcare provider profile · identity verified
James Matthew Wilson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NORTON, VA · NPI 1205981115
Verified facts
What the public records show
CMS Open Payments records show James Matthew Wilson, M.D. received $2,472.93 in general payments during 2025 across 169 reported records.
Novo Nordisk Inc accounted for 15.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $383.37 | 15.5% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $351.08 | 14.2% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $270.30 | 10.9% | 25 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $243.60 | 9.8% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $229.41 | 9.3% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $161.41 | 6.5% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $160.60 | 6.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.28 | 6.0% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $135.29 | 5.5% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $72.47 | 2.9% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.33 | 1.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.53 | 1.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.41 | 1.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.96 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.22 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.17 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.35 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.64 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $20.21 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.30 | 0.7% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $17.27 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.73 | 0.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $14.00 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,472.93 | 169 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $288.00 | 13 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $229.41 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $189.66 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $161.41 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $161.32 | 14 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $160.60 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $151.12 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.54 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $135.41 | 17 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $135.41 | 17 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $135.29 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $131.81 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.04 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $111.65 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $102.45 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $95.99 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $93.33 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.67 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $72.47 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $37.63 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.96 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.35 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $7.76 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $7.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 204 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 32 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
204 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 613 | 108 |
| Gabapentin | Gabapentin | 560 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 414 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 373 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 84 |
| Omeprazole | Omeprazole | 330 | 76 |
| Prednisone | Prednisone | 302 | 148 |
| Lisinopril | Lisinopril | 292 | 77 |
| Losartan Potassium | Losartan Potassium | 289 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 74 |
| Tramadol Hcl | Tramadol Hcl | 283 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 270 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 67 |
| Celecoxib | Celecoxib | 246 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 55 |
| Metformin Hcl | Metformin Hcl | 236 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 215 | 52 |
| Eliquis | Apixaban | 204 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 22 |
| Meloxicam | Meloxicam | 189 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 181 | 42 |
| Montelukast Sodium | Montelukast Sodium | 173 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 36 |
| Clonazepam | Clonazepam | 155 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 34 |
| Furosemide | Furosemide | 154 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 27 |
| Carvedilol | Carvedilol | 146 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 41 |
| Spironolactone | Spironolactone | 145 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 34 |
| Trazodone Hcl | Trazodone Hcl | 141 | 25 |
| Donepezil Hcl | Donepezil Hcl | 124 | 27 |
| Cefdinir | Cefdinir | 122 | 91 |
| Allopurinol | Allopurinol | 117 | 27 |
| Simvastatin | Simvastatin | 117 | 23 |
| Potassium Chloride | Potassium Chloride | 112 | 29 |
| Ibuprofen | Ibuprofen | 109 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 15 |
| Famotidine | Famotidine | 104 | 25 |
| Lorazepam | Lorazepam | 99 | 20 |
| Alprazolam | Alprazolam | 97 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 25 |
| Buspirone Hcl | Buspirone Hcl | 95 | 23 |
| Cephalexin | Cephalexin | 94 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 14 |
| Atenolol | Atenolol | 87 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 15 |
| Glipizide | Glipizide | 83 | 20 |
| Pregabalin | Pregabalin | 83 | suppressed |
| Ozempic | Semaglutide | 82 | 18 |
| Sertraline Hcl | Sertraline Hcl | 79 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 59 |
| Mirtazapine | Mirtazapine | 75 | 15 |
| Sucralfate | Sucralfate | 75 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | suppressed |
| Jardiance | Empagliflozin | 67 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 66 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | suppressed |
| Ezetimibe | Ezetimibe | 64 | 15 |
| Metformin Hcl Er | Metformin Hcl | 64 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 49 |
| Azithromycin | Azithromycin | 61 | 39 |
| Bupropion Xl | Bupropion Hcl | 61 | 14 |
| Glyburide | Glyburide | 60 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 29 |
| Finasteride | Finasteride | 59 | 14 |
| Nabumetone | Nabumetone | 58 | 14 |
| Terazosin Hcl | Terazosin Hcl | 58 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | 12 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Fenofibrate | Fenofibrate,micronized | 54 | 13 |
| Torsemide | Torsemide | 54 | 14 |
| Temazepam | Temazepam | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 15 |
| Doxepin Hcl | Doxepin Hcl | 45 | suppressed |
| Glimepiride | Glimepiride | 43 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | suppressed |
| Nateglinide | Nateglinide | 40 | 12 |
| Baclofen | Baclofen | 39 | 18 |
| Meclizine Hcl | Meclizine Hcl | 39 | 21 |
| Levofloxacin | Levofloxacin | 38 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Buprenorphine | Buprenorphine | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 13 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Ibu | Ibuprofen | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 29 | 13 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 23 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,472.93 · 169 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CREON, CRYSVITA, CeQur Simplicity, ELIQUIS, EVENITY, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VERQUVO, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error